As of Thursday close, Orchard Therapeutics plc’s (NASDAQ:ORTX) stock was down -$0.02, moving down -3.54 percent to $0.42. The average number of shares traded per day over the past five days has been 910,340 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0886 fall in that time frame. In the last twenty days, the average volume was 560,135, while in the previous 50 days, it was 598,028.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ORTX stock retreated -40.05%. Shares of the company fell to $0.4120 on 05/12/22, the lowest level in the past month. A 52-week high of $5.99 was reached on 01/03/22 after having rallying from a 52-week low of $0.42. Since the beginning of this year, ORTX’s stock price has dropped by -67.99% or -$0.8975, and marked a new high 1 time. However, the stock has declined by -92.95% since its 52-week high.
Orchard Therapeutics plc (ORTX) last reported insider trading activity 42 days ago on Apr 01. THOMAS FRANK E, the of the company, purchased of 10,000 shares for $0.75 on Apr 01. It resulted in a $7,474 investment by the insider. Gaspar Bobby added 15,000 shares at an average price of $0.74 on Apr 01. The insider now owns 366,158 shares following the transaction.
The stock’s beta is 1.19. Besides these, the trailing price-to-sales (P/S) ratio of 34.87, the price-to-book (PB) ratio of 0.26.
In the three months ended September 29, Orchard Therapeutics plc’s quick ratio stood at 6.40, while its current ratio was 6.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.15, and the total debt-to-equity ratio was 0.16. On the profitability front, the trailing twelve-month gross margin is 86.50% percent. Based on annual data, ORTX earned $1.45 million in gross profit and brought in $1.68 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -58.20%. Return on equity (ROE) for the past 12 months was -57.20%.
In Orchard Therapeutics plc’s quarter-end financial report for September 29, it reported total debt of $32.09 million against cash and short-term investments of $164.2 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ORTX’s revenue rose 100.0% to $1.19 million during the quarter, while net income inched up to $0.48 million. While analysts expected Orchard Therapeutics plc to report -$0.25 quarterly earnings, the actual figure was -$0.29 per share, beating the consensus estimate by -16.00%. During the quarter, the company generated -$35.53 million in EBITDA. The liabilities of Orchard Therapeutics plc were 112.46 million at the end of its most recent quarter ended September 29, and its total debt was $60.84 million. The value of shareholders’ equity is $125.83 million.
This quick technical analysis looks at Orchard Therapeutics plc’s (ORTX) price momentum. With a historical volatility rate of 57.89%, the RSI 9-day stood at 15.99% on 12 May.
With respect to its five-day moving average, the current Orchard Therapeutics plc price is down by -17.34% percent or -$0.0886. At present, ORTX shares trade -38.69% below its 20-day simple moving average and -65.37% percent below its 100-day simple moving average. However, the stock is currently trading approximately -52.77% below its SMA50 and -85.68% below its SMA200.
Stochastic coefficient K was 7.64% and Stochastic coefficient D was 9.56%, while ATR was 0.0541. Given the Stochastic reading of 3.94% for the 14-day period, the RSI (14) reading has been calculated as 21.29%. As of today, the MACD Oscillator reading stands at -0.0546, while the 14-day reading stands at -0.0937.
Orchard Therapeutics plc (ORTX) has been rated Overweight by analysts. According to 1 brokerage firm, ORTX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Orchard Therapeutics plc stock as buy, with 4 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $1.00 – $7.00. Based on these forecasts, analysts predict Orchard Therapeutics plc (ORTX) will achieve an average price target of $4.14.